Neurocrine Biosciences Inc (NBIX)vsTeva Pharma Industries Ltd ADR (TEVA)
NBIX
Neurocrine Biosciences Inc
$163.88
-2.07%
HEALTHCARE · Cap: $16.06B
TEVA
Teva Pharma Industries Ltd ADR
$34.43
-2.71%
HEALTHCARE · Cap: $40.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 459% more annual revenue ($17.35B vs $3.10B). NBIX leads profitability with a 21.5% profit margin vs 9.0%. NBIX appears more attractively valued with a PEG of 0.45. NBIX earns a higher WallStSmart Score of 81/100 (A-).
NBIX
Exceptional Buy81
out of 100
Grade: A-
TEVA
Strong Buy66
out of 100
Grade: B-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Revenue surging 42.2% year-over-year
Earnings expanding 2311.0% YoY
Safe zone — low bankruptcy risk
Keeps 22 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Weak financial health signals
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Revenue Growth, EPS Growth. Profitability is solid with margins at 21.5% and operating margin at 22.8%. Revenue growth of 42.2% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.
Bear Case : NBIX
The primary concerns for NBIX are Piotroski F-Score.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
NBIX profiles as a growth stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.85 — expect wider price swings.
NBIX is growing revenue faster at 42.2% — sustainability is the question.
NBIX generates stronger free cash flow (137M), providing more financial flexibility.
Bottom Line
NBIX scores higher overall (81/100 vs 66/100), backed by strong 21.5% margins and 42.2% revenue growth. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?